Clinical Trial · NCT02139150

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

Overview

The purpose of this study is to see if PET/CT scans that use a radioactive substance called \[18F\] fluorothymidine (FLT), can detect and monitor changes in the tumor. Radioactive substances are used with PET/CT scans to "see" cancer cells, and are also called radiotracers. FLT is a new radiotracer that has been given to people in prior studies. FLT PET/CT is an experimental scan unlike FDG (fluorodeoxyglucose) PET scan which is a standard clinical scan and is commonly used. The investigators would like to know if there is any evidence of early treatment response by obtaining FLTPET/ CT scans before and after treatment.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

N/A

Contacts

Heiko Schöder, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02139150

Eligibility

Inclusion

Patients who have consented to a therapeutic protocol for the treatment of their cancer.
Patients with histologically-confirmed (confirmation done at MSKCC) malignancies.

Exclusion

Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia).
Women who are pregnant or breast-feeding.